pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Rare Disease · news · pharmadog
← back to Rare Disease
News mentioning Rare Disease
497
stories
9d
Beam preps FDA run for industry-first base-edited therapy after pivotal sickle cell success
biospace
9d
STAT+: PepGen says early trial for muscular dystrophy drug looks promising
stat
10d
Lilly to seek second sleep apnea approval after Foundayo reduces disease severity in Phase 3
biospace
10d
Update: Compass submits psilocybin depression drug for approval after stock wobbles
biospace
10d
Details from Novartis’ failed cardiovascular trial offer ‘little silver lining’ for rivals
biospace
10d
Update: FDA investigates Novartis' Zolgensma following 9 cases of tumors in treated patients
biospace
10d
FDA’s new rare disease framework aims to leverage patient voices for better innovation
biospace
13d
STAT+: New tumor cases show common gene therapy tool can come with risk
stat
13d
Forge’s Piteri-Molina on AI, Ohio and what’s next for gene therapy manufacturing
biospace
13d
Sarepta quits enrolling for confirmatory Phase 3 trial of Elevidys
endpoints
13d
Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down
biopharma dive
14d
STAT+: Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy
stat
14d
STAT+: Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy
stat
14d
Novartis confirms 9 reported cases of tumors in patients treated with Zolgensma
biospace
14d
STAT+: A possible comeback for a failed sickle cell gene therapy
stat
14d
Coveted metabolic gem Rhythm reportedly gets $10B offer from AstraZeneca
biospace
14d
Single-payer health care system proponents were thrown a big bone this election
stat
14d
STAT+: In China, a flood of controversial clinical trials slows to a trickle
stat
15d
Sanofi’s axing of Nurix STAT6 program ‘not a target-related issue’
biospace
15d
STAT+: Ultragenyx cuts staff after another study fails
stat
15d
Charles River teams up with Ipsen to use virtual control groups in toxicology studies
fiercebiotech
15d
Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review
biospace
16d
STAT+: Servier’s $1.55 billion muscular dystrophy drug fails first major test
stat
16d
Neurocrine defends Prader-Willi drug after another patient death
biospace
17d
UniQure snags May Day decision date for Huntington’s gene therapy after arduous year
biospace
17d
Significant stock movers of October: Biohaven climbs, ArriVent dives
biospace
17d
Plug-and-play gene therapy: FDA executes on vision that’s been in the works for years
biospace
17d
BridgeBio gears up for rare muscular dystrophy launch with FDA approval in sight
biospace
20d
FDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory Papillomatosis
fda press
20d
AstraZeneca employs $1.5B cost savings to reinvest back into growth
biospace
← prev
page 2 of 17
next →